

Ann M Reed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4560367/publications.pdf>

Version: 2024-02-01

55
papers

5,015
citations

147801

31
h-index

182427

51
g-index

90
all docs

90
docs citations

90
times ranked

3689
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1955-1964.	0.9	754
2	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-controlled phase trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 314-324.	6.7	514
3	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017, 69, 2271-2282.	5.6	391
4	Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. <i>Lancet</i> , The, 2008, 371, 2201-2212.	13.7	383
5	An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity. <i>Molecular Medicine</i> , 2007, 13, 59-68.	4.4	262
6	Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. <i>Arthritis and Rheumatology</i> , 2014, 66, 740-749.	5.6	210
7	Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. <i>Arthritis and Rheumatism</i> , 2009, 60, 3436-3446.	6.7	198
8	Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2004, 50, 1595-1603.	6.7	195
9	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. <i>Arthritis and Rheumatism</i> , 1999, 42, 2213-2219.	6.7	194
10	Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations. <i>Mayo Clinic Proceedings</i> , 2013, 88, 83-105.	3.0	145
11	History of infection before the onset of juvenile dermatomyositis: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. <i>Arthritis and Rheumatism</i> , 2005, 53, 166-172.	6.7	130
12	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.9	127
13	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017, 3, e000507.	3.8	115
14	Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. <i>Arthritis Care and Research</i> , 2012, 64, 546-553.	3.4	101
15	Update on outcome assessment in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 303-318.	8.0	100
16	Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. <i>Journal of Rheumatology</i> , 2010, 37, 1953-1961.	2.0	90
17	Clinical Characteristics of Children With Juvenile Dermatomyositis: The Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Arthritis Care and Research</i> , 2014, 66, 404-410.	3.4	82
18	Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. <i>Rheumatology</i> , 2017, 56, 247-254.	1.9	82

#	ARTICLE	IF	CITATIONS
19	Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. <i>Arthritis Care and Research</i> , 2010, 62, 219-225.	3.4	77
20	Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. <i>Arthritis and Rheumatism</i> , 2012, 64, 4078-4086.	6.7	76
21	Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa. <i>JAMA Dermatology</i> , 2015, 151, 1230.	4.1	75
22	Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. <i>Rheumatology</i> , 2016, 55, 991-999.	1.9	75
23	Genetic and environmental risk factors for idiopathic inflammatory myopathies. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, 891-916.	1.9	63
24	Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 957-962.	5.6	53
25	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 782-791.	0.9	51
26	Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. <i>Journal of Rheumatology</i> , 2017, 44, 110-116.	2.0	43
27	Biologic predictors of clinical improvement in rituximab-treated refractory myositis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 257.	1.9	42
28	Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. <i>JCI Insight</i> , 2017, 2, .	5.0	35
29	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. <i>Journal of Rheumatology</i> , 2015, 42, 2419-2426.	2.0	34
30	BAFF Expression Correlates with Idiopathic Inflammatory Myopathy Disease Activity Measures and Autoantibodies. <i>Journal of Rheumatology</i> , 2013, 40, 294-302.	2.0	33
31	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects. <i>Rheumatology</i> , 2017, 56, 1884-1893.	1.9	33
32	Juvenile Dermatomyositis. <i>Paediatric Drugs</i> , 2002, 4, 315-321.	3.1	32
33	Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 117-124.	2.0	25
34	Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. <i>World Journal of Pediatrics</i> , 2020, 16, 31-43.	1.8	22
35	T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 188.	3.5	21
36	The inflammatory milieu in idiopathic inflammatory myositis. <i>Current Rheumatology Reports</i> , 2009, 11, 295-301.	4.7	20

#	ARTICLE	IF	CITATIONS
37	Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. <i>Journal of Inflammation</i> , 2015, 12, 29.	3.4	16
38	Brief Report: HLA*DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2772-2777.	5.6	15
39	Immunological Biomarkers in Dermatomyositis. <i>Current Rheumatology Reports</i> , 2015, 17, 68.	4.7	13
40	A Clinically and Biologically Based Subclassification of the Idiopathic Inflammatory Myopathies Using Machine Learning. <i>ACR Open Rheumatology</i> , 2020, 2, 158-166.	2.1	12
41	Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis. <i>ACR Open Rheumatology</i> , 2019, 1, 83-89.	2.1	10
42	Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study. <i>Journal of Rheumatology</i> , 2021, 48, 114-122.	2.0	9
43	Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 655-63.	0.8	9
44	Microchimerism in children with rheumatic disorders: What does it mean?. <i>Current Rheumatology Reports</i> , 2003, 5, 458-462.	4.7	8
45	Recent advances in juvenile dermatomyositis. <i>Current Rheumatology Reports</i> , 2005, 7, 94-98.	4.7	6
46	Juvenile Dermatomyositis. <i>Paediatric Drugs</i> , 2002, 4, 315-321.	3.1	6
47	Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. <i>Clinical Rheumatology</i> , 2018, 37, 1011-1015.	2.2	5
48	Chimerism in myositis. <i>Current Rheumatology Reports</i> , 2003, 5, 421-424.	4.7	4
49	Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients <i>vs</i> healthy control subjects. <i>Rheumatology</i> , 2022, 61, 1699-1708.	1.9	4
50	Gene Expression Profiles of Treatment Response and <sc>Non-Response</sc> in Children With Juvenile Dermatomyositis. <i>ACR Open Rheumatology</i> , 2022, 4, 671-681.	2.1	4
51	Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients. <i>SAGE Open Medicine</i> , 2013, 1, 205031211351440.	1.8	1
52	Pediatrics Practice at Mayo Clinic—A Historical Vignette. <i>Mayo Clinic Proceedings</i> , 2014, 89, e23-e25.	3.0	0
53	Mineral Oil Aspiration Related Juvenile Idiopathic Arthritis. <i>Case Reports in Pulmonology</i> , 2015, 2015, 1-3.	0.3	0
54	The Role of a Division of Quantitative Sciences Division in Enhancing Academic Productivity of a Department of Pediatrics. <i>Journal of Pediatrics</i> , 2017, 180, 4-5.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Management Considerations: Juvenile Dermatomyositis. , 2020, , 285-298.		0